高级检索
当前位置: 首页 > 详情页

Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients

文献详情

资源类型:
机构: [1]Graduate School of Southern Medical University, 510515 Guangzhou, China [2]Department of Urology, Traditional Chinese Medicine Hospital of Luogang District, 510530 Guangzhou, China [3]Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, 510630 Guangzhou, China [4]Department of Urology, The First Affiliated Hospital, Jinan University, 510630 Guangzhou, China
出处:
ISSN:

关键词: Polymorphism Prognosis Renal cell carcinomas VEGF

摘要:
We investigated the association of three single nucleotide polymorphisms (SNPs) in VEGF gene with the prognosis of renal cell carcinoma (RCC) and its association with clinical characteristics of RCC, such as tumor stages, metastasis, and tumor size. Polymerase chain reaction (PCR) restriction fragment length polymorphism analysis was used to genotype specimens for three polymorphisms (−2578C/A, −1154G/A, and −634G/C) in the VEGF gene. Hazard ratios (HRs) and their confidence intervals (CIs) were used to analyze the association of three SNPs in the VEGF gene with survival time using a multivariate Cox proportional hazards model. Frequencies of VEGF−2578AA genotype and A allele were significantly higher in patients with III–IV tumor stage or larger tumor size when compared with CC genotype. Moreover, frequencies of VEGF−634CC genotype and C allele were significantly higher in patients with tumor size >4 cm when compared with −634GG genotype. By Cox proportional hazards model, patients carrying VEGF−2578AA genotype and A allele significantly increased the risk of death from RCC, with the adjusted HRs (95 % CI) of 2.23 (1.15–4.36) and 1.55 (1.11–2.17), respectively. Our study suggests that VEGF−2578C/A and VEGF−634G/C polymorphisms may have effects on the prognosis of RCC. This finding might help in clarifying the mechanisms of RCC development and progression. © 2014, International Society of Oncology and BioMarkers (ISOBM).

语种:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
第一作者:
第一作者机构: [1]Graduate School of Southern Medical University, 510515 Guangzhou, China [2]Department of Urology, Traditional Chinese Medicine Hospital of Luogang District, 510530 Guangzhou, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号